VR Adviser, LLC Q3 2022 Filing
Filed November 14, 2022
Portfolio Value
$680.6B
Holdings
31
Report Date
Q3 2022
Filing Type
13F-HR
All Holdings (31 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | 1T7Tricida Inc | 9,050,064 | $94.8B | 13.93% | |
| 2 | ACRSAclaris Therapeutics Inc | 4,563,962 | $71.8B | 10.55% | |
| 3 | COGTCogent Biosciences Inc | 4,038,117 | $60.2B | 8.85% | |
| 4 | RLMDRelmada Therapeutics Inc | 1,518,056 | $56.2B | 8.26% | |
| 5 | VRDNViridian Therapeutics Inc | 2,130,308 | $43.7B | 6.42% | |
| 6 | GHRSGH Research PLC | 3,333,154 | $38.7B | 5.69% | |
| 7 | ATYRDBV Technologies SA | 9,300,000 | $32.5B | 4.78% | |
| 8 | PLRXPliant Therapeutics Inc | 1,080,000 | $22.6B | 3.31% | |
| 9 | MISTMilestone Pharmaceuticals Inc | 2,425,737 | $22.3B | 3.28% | |
| 10 | TERNTerns Pharmaceuticals Inc | 3,707,891 | $21.8B | 3.21% | |
| 11 | MRNS*Marinus Pharmaceuticals Inc | 3,156,803 | $21.0B | 3.08% | |
| 12 | GOSSGossamer Bio Inc | 1,747,000 | $20.9B | 3.07% | |
| 13 | ANNXAnnexon Inc | 3,220,050 | $19.9B | 2.92% | |
| 14 | TILInstil Bio Inc | 4,105,779 | $19.9B | 2.92% | |
| 15 | —Akouos Inc | 2,800,566 | $18.9B | 2.78% | |
| 16 | —Dice Therapeutics Inc | 764,979 | $15.5B | 2.28% | |
| 17 | AVTEAerovate Therapeutics Inc | 833,927 | $13.8B | 2.03% | |
| 18 | LIANYLianBio | 5,378,341 | $10.8B | 1.58% | |
| 19 | FULCFulcrum Therapeutics Inc | 1,200,000 | $9.7B | 1.43% | |
| 20 | INZYInozyme Pharma Inc | 2,709,987 | $7.3B | 1.07% | |
| 21 | VTYXVentyx Biosciences Inc | 207,925 | $7.3B | 1.07% | |
| 22 | —Prometheus Biosciences Inc | 121,663 | $7.2B | 1.05% | |
| 23 | YB4PSavara Inc | 4,555,038 | $7.1B | 1.04% | |
| 24 | PRVBUSDProvention Bio Inc | 1,118,653 | $5.0B | 0.74% | |
| 25 | ALTAltimmune Inc | 369,306 | $4.7B | 0.69% | |
| 26 | TRVITrevi Therapeutics Inc | 3,050,022 | $4.7B | 0.69% | |
| 27 | LYRALyra Therapeutics Inc | 924,170 | $4.6B | 0.68% | |
| 28 | IMCRImmunocore Holdings PLC | 94,605 | $4.4B | 0.65% | |
| 29 | ATYRaTyr Pharma Inc | 1,398,889 | $4.2B | 0.62% | |
| 30 | RLYBRallybio Corp | 268,532 | $3.9B | 0.57% | |
| 31 | —Affimed NV | 1,428,571 | $2.9B | 0.43% | |
| 32 | TCE2Celldex Therapeutics Inc | 75,000 | $2.1B | 0.31% |